Anti-type I interferon antibodies as a cause of severe COVID-19.

COVID-19 ranges from asymptomatic through to respiratory failure and death. Although specific pre-existing conditions such as age and male sex have been associated with poor outcomes, we remain largely ignorant of the mechanisms predisposing to severe disease. In this study, the authors discovered that approximately 10% of 987 patients with life-threatening COVID-19 harbored neutralizing antibodies to Type I interferons (IFNs) ¹ . They demonstrated that these antibodies could neutralize high concentrations of the corresponding IFN and could rescue SARS-CoV-2 infection from inhibition by IFN in vitro . Importantly, anti-IFN antibodies were associated with low levels of serum IFN. These observations suggest that disease severity in these individuals results from a failure to control SARS-CoV-2 replication because of antibody-mediated IFN inhibition. The study suggests specific treatments and diagnostics for this class of severe COVID-19.
Competing Interests: Adrian Hayday is a co-author and/or ongoing collaborator with Kai Kisand and Pärt Peterson, authors who contributed to the evaluated paper. He is also a Board Member and equity holder in ImmunoQure AG, a company that has identified naturally occurring human anti-cytokine antibodies targeting Type I interferon for potential use in the clinic.
(Copyright: © 2022 Faculty Opinions Ltd.)